Characterization of CD30

Reed-Sternberg cell

In 1982 Stein and colleagues identified a new monoclonal antibody, Ki-1, that was specific for Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma (HL) and a small population of lymphoid cells.1,2 The antigen recognized by Ki-1, designated as CD30, was found to be expressed not only in HL, but also on large-cell neoplasms subsequently designated anaplastic large cell lymphoma (ALCL).3,4

CD30 is a transmembrane glycoprotein with a molecular weight of 120 kDa.5,6 It is a member of the tumor necrosis factor receptor (TNFR) superfamily, which is likely to be crucial for regulating proliferation and differentiation of lymphocytes.7 An 85-kDa proteolytic fragment defined as soluble CD30 (sCD30) can be detected in the sera of patients with CD30-positive lymphomas and is also found in some patients with bone cancer, rheumatoid arthritis, atopic dermatitis and other reactive disorders, particularly during the acute phase of the disease.8,9,10,11 It has been suggested that high serum levels of sCD30 represent an independent predictor of disease progression and poor prognosis for patients with CD30-positive lymphomas.8,12

References

  1. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65-67.
  2. Stein H, Gerdes J, Schwab U, et al. Identification of Hodgkin and Sternberg-Reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer. 1982;30(4):445-459.
  3. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848-858.
  4. Stein H, Foss H-D, Dürkop H, et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681-3695.
  5. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell. 1992;68(3):421-427.
  6. Gruss H-J, Duyster J, Herrmann F. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin’s disease. Ann Oncol. 1996;7(suppl 4):19-26.
  7. de Bruin PC, Gruss H-J, van der Valk P, Willemze R, Meijer CJLM. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. Leukemia. 1995;9(10):1620-1627.
  8. Gerber H-P. Emerging immunotherapies targeting CD30 in Hodgkin’s lymphoma. Biochem Pharmacol. 2010;79(11):1544-1552.
  9. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90(2):157-164.
  10. Holzer G, Pfandlsteiner T, Blahovec H, Trieb K, Kotz R. Serum concentrations of sCD30 and sCD40L in patients with malignant bone tumours. Wien Med Wochenschr. 2003;153(1-2):40-42.
  11. Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo, I: partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol. 1989;19(1):157-162.
  12. Diehl V, Bohlen H, Wolf J. CD30: cytokine-receptor, differentiation marker or a target molecule for specific immune response? Ann Oncol. 1994;5(4):300-302.